Verrica Pharmaceuticals Inc. (VRCA) intrinsic value & 10-year financials
Verrica Pharmaceuticals Inc. (VRCA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 31.2% a year to $35.6M, with an average return on invested capital of -638.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.60
- Market cap
- $38.3M
- Revenue (FY2025)
- $35.6M
- Revenue growth (10-yr CAGR)
- 31.2%
- ROIC (10-yr avg)
- -638.3%
- Free cash flow (FY2025)
- -$17.6M
VRCA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $35.6M | -$17.9M | -$1.68 | -$17.6M | -34.2% | 157.9% |
| FY2024 | $7.6M | -$76.6M | -$1.48 | -$61.0M | -871.3% | 829.6% |
| FY2023 | $5.1M | -$67.0M | -$1.48 | -$38.9M | -1283.4% | -6526.9% |
| FY2022 | $9.0M | -$24.5M | -$0.72 | -$19.0M | -235.8% | -63.6% |
| FY2021 | $12.0M | -$35.1M | -$1.30 | -$28.5M | -257.6% | -58.8% |
| FY2020 | — | -$42.7M | — | -$31.7M | — | -74.2% |
| FY2019 | — | -$28.2M | — | -$28.1M | — | -50.5% |
| FY2018 | — | -$20.6M | — | -$18.1M | — | -50.1% |
| FY2017 | — | -$4.5M | — | — | — | 91.9% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Verrica Pharmaceuticals Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Verrica Pharmaceuticals Inc. has historically struggled to out-earn its cost of capital, averaging just -29.0% ROIC.
Verrica Pharmaceuticals Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Verrica Pharmaceuticals Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-55.80 per share.